AI Defense Stock VisionWave Holdings (Nasdaq: $VWAV) Assembles Due-Diligence Team for Solar Drone Acquisition; @VWAVInc

 

AI Defense Stock VisionWave Holdings (Nasdaq: $VWAV) Assembles Due-Diligence Team for Solar Drone Acquisition; @VWAVInc

 

VisionWave Holdings Enters Final Due Diligence for Proposed Solar Drone Acquisition; Intends to Explore Vision-RF Integration

 

WEST HOLLYWOOD, Calif., November 20, 2025 —( Investorideas.com Newswire) Breaking Defense stock news- VisionWave Holdings, Inc. (Nasdaq: VWAV) announced today that it has completed assembling its full due-diligence team for the proposed acquisition of Solar Drone Ltd., a wholly-owned subsidiary of BladeRanger Ltd. (TASE: BLRN), as previously disclosed in the Company’s LOI and Form 8-K filings.

 

The Company has mobilized a combined force of legal, technical, regulatory, financial, strategic, and advisory professionals who are now working day and night—both on-site in Israel and remotely from the United States—to advance the transaction toward execution of the definitive agreement as soon as practicable.

 

In addition to commercial applications, if the acquisition is completed, VisionWave intends to explore potential integration of its Vision-RF sensing and autonomy technologies into Solar Drone’s platform, with the goal of enhancing the drone’s capabilities for homeland-security, emergency-response, and critical-infrastructure protection missions. This reflects the Company’s continuing expansion of its Vision-RF ecosystem, most recently demonstrated in VisionWave’s recent provisional patent application related to WaveStrike.

 

Paid News Dissemination on behalf of VWAV 

 

Read this news, featuring VWAV in full at https://www.investorideas.com/CO/BNIX/news/2025/11201-visionwave-solar-drone-acquisition-due-diligence.asp

 

Comprehensive Review of the Transaction Underway

As part of the current diligence phase, VisionWave and its advisors are conducting a full review of the proposed acquisition, including:

·         Commercial readiness and deployment use-cases

·         Technology verification, IP ownership, and integration feasibility

·         Manufacturing pathways and operational scalability

·         Financial, revenue, and cost-structure validation

·         Tax, legal, corporate, and M&A compliance

·         Regulatory considerations across the U.S., Israel, and international markets

 

The Company emphasized that this phase is progressing on schedule, with teams embedded directly at Solar Drone’s facilities to ensure full validation prior to finalizing the definitive Share Purchase Agreement.

 

Professional Advisors

VisionWave has engaged the following to advise on the proposed transaction:

·         Fleming PLLC as U.S. securities and transaction counsel

·         An Israeli legal counsel

·         A financial and tax due-diligence advisor

 

VisionWave Leadership & Technical Team Working On-Site

Members of VisionWave’s senior technical and leadership team are conducting on-site due diligence and technology evaluation at Solar Drone’s facilities in Israel.

 

Integrating Vision-RF Into Solar Drone

Beyond traditional industrial and commercial use-cases, VisionWave will seek to deploy its Vision-RF technology suite into the Solar Drone platform. Potential future capabilities of an integrated platform could include:

·         All-weather, day/night RF-native situational awareness

·         Obscurant-penetrating sensing

·         Low-signature perimeter and border monitoring

·         Emergency-response and critical-infrastructure protection

·         AI-driven autonomous navigation and detection

 

Vision-RF is the Company’s patented multi-modal RF imaging and perception stack, recently expanded through its WaveStrike fire-control patent filing, which uses RF-native computing to produce visualized outputs and predictive cues.

 

Leadership Commentary

Douglas Davis, Executive Chairman of VisionWave, stated:

“We now have a world-class, cross-border due-diligence team operating on the ground in Israel and in the U.S. This assembled group—led by Fleming PLLC, alongside An Israeli legal counsel a domestic financial and tax due-diligence advisor, and our own VisionWave technical leadership—is working to advance this transaction. The goal of pursuing the integration of Vision-RF into Solar Drone if completed could represent a transformative step for both companies.”

 

Ambassador (Ret.) Ned L. Siegel, VisionWave Advisory Board, said:

“The opportunity to apply Vision-RF technology to Solar Drone’s platform opens meaningful possibilities for homeland-security and emergency-response missions. Our entire team is approaching this evaluation with rigor and urgency.”

 

Next Steps

The transaction remains subject to due diligence, negotiation and execution of definitive agreements, regulatory approvals and customary closing conditions. There can be no assurance that a definitive agreement will be reached or that the transaction will close.

 

About VisionWave Holdings Inc.

VisionWave (Nasdaq: VWAV) is a defense-technology company specializing in AI-powered sensing, on-edge autonomy, and threat-response systems. Its Evolved Intelligence™ engine and Vision-RF sensing platform enable real-time perception, prediction, and control for military and security applications across air, land, and sea domains. VisionWave is headquartered in West Hollywood, California, with operations in the United States, Israel, and the UAE. For more information, visit www.vwav.inc.

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to statements regarding Zacks Small-Cap Research's views on the Company’s projected expected revenue growth, commercial transition, inflection point, strategic initiatives, and market position as described in the Zacks report. These statements are based on current expectations of Zacks Small-Cap Research and are subject to risks and uncertainties that could cause actual results to differ materially, including but not limited to: (i) failure to successfully convert pilot programs into commercial production contracts; (ii) delays or issues in scaling production; (iii) competitive pressures in the defense-AI sector; (iv) dependence on key partnerships with Tier-1 contractors and government entities; (v) regulatory, execution, and funding risks (including potential dilution); and (vi) other risks detailed in the Zacks report and in Readers are cautioned not to place undue reliance on these forward-looking statements.  For further information on risk factors, please refer to VisionWave’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update these statements after the date of this release.

 

Investor Contact: investors@vwav.inc

Website: https://www.vwav.inc

 

VisionWave is a Featured Defense stock on Investorideas.com

Research more defense stocks at Investorideas stock directory  https://www.investorideas.com/Companies/HomelandDefense/stock_list.asp

 

Disclaimer/Disclosure: VisionWave Holdings, Inc. is a paid for featured defense company on Investorideas.com. Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all.

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas https://www.investorideas.com/Advertise/

 

Follow & Contact

Follow us on X: @investorideas   @stocknewsbites

Facebook: https://www.facebook.com/Investorideas

YouTube: https://www.youtube.com/c/Investorideas

Actinium's (NYSE American: ATNM) High-Stakes Sprint: Betting Big on the Explosive Global Cancer Radiotherapy Boom; @ActiniumPharma

 

Actinium's (NYSE American: ATNM) High-Stakes Sprint: Betting Big on the Explosive Global Cancer Radiotherapy Boom; @ActiniumPharma

 

Stocks Mentioned: (NYSE American: $ATNM), (NYSE: $NVS), (NYSE: $LLY)

 

November 17, 2025- Investorideas.com, a go-to investing platform covering biotech and pharma stocks issues a snapshot looking at the radiotherapy cancer market, featuring Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), a pioneer in the development of differentiated, targeted radiotherapies intended to meaningfully improve outcomes for patients with advanced cancers.  Actinium is deploying its technologies, capabilities and intellectual property with approximately 250 issued and pending patents worldwide, to develop next-generation radiotherapies focused on solid tumors, hematology and conditioning for cellular therapies.

 

The targeted radiotherapies for cancer market is experiencing significant growth, driven by advancements in technology and investment.

 

Paid news dissemination on behalf of Actinium

Read this article, featuring ATNM in full at https://www.investorideas.com/news/2025/biotech/11171-actinium-atnm-cancer-radiotherapy-market-growth-biotech-stock-analysis.asp

 

The cancer radiotherapy market, particularly the radioligand therapy (RLT) segment, is expanding swiftly. Novartis (NYSE: NVS), a dominant player in this arena, is targeting RLT revenue by broadening its portfolio of approved treatments and advancing its development pipeline. According to multiple sources, Novartis CEO Vas Narasimhan has estimated that the market for radioligand therapy (RLT) could be valued at between $25 billion and $30 billion.

 

Also reported in a Briefglance.com recent article, “Novartis is bolstering its position in the rapidly expanding field of targeted cancer therapy with a new radioligand therapy (RLT) manufacturing facility in Carlsbad, California. The investment underscores the growing demand for personalized cancer treatments and positions Novartis to capitalize on a market projected for significant growth over the next decade.”

 

Continued:

Novartis’s Pluvicto, approved for prostate cancer sales exceeded $1.39 billion in 2024 and expected to reach approximately $4.3 billion by 2030. “.

 

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) reporting in its recent 10Q filing: “Recently prioritized as our lead program, ATNM-400, is a highly innovative, first-in-class, and pan-tumor Actinium-225 (“Ac-225”) alpha-emitter targeted radiotherapy candidate with preclinical data in prostate cancer, non-small cell lung cancer (“NSCLC”) and breast cancer.

“We believe ATNM-400 has the potential to address critical gaps across multiple treatment settings in each of these targeted indications and can therefore address large patient populations. Actimab-A is our most advanced clinical-stage product candidate, which utilizes an antibody linked to Ac-225 to target CD33, a cell surface protein that Actimab-A is designed to target, that is expressed ubiquitously in acute myeloid leukemia (“AML”) and myelodysplastic syndromes (“MDS”) and on myeloid derived suppressor cells (“MDSC”).”

 

“We are evaluating Actimab-A’s potential to synergize with immune checkpoint inhibitors (“ICIs”) such as programmed cell death 1 (“PD-1) inhibitors in solid tumors by depleting MDSC immune cells. Iomab-ACT is our next-generation targeted conditioning agent we are developing with the intent to improve patient access to, and outcomes with, cellular therapies such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease (“SCD”).”

 

Commenting on the market opportunity in their 10Q, Actinium notes,”With the approval of Novartis’ (NYSE: NVS) Pluvicto® for patients with mCRPC post-taxane therapy and post ARPI therapy and prior to taxane therapy, targeted-radiotherapy has become a prominent component of the metastatic prostate cancer treatment paradigm. Pluvicto® generated sales of approximately $1.4 billion in the first nine months of 2025. In June 2025, Novartis announced it expects to file an FDA submission in the second half of 2025 for Pluvicto® in metastatic hormone sensitive prostate cancer (“mHSPC”) that could add approximately 42,500 additional patients to the addressable market for Pluvicto®. With approximately one-third of patients not responding to PSMA-directed radiotherapy and that virtually all patients will progress on PSMA-directed radiotherapy within 12 months, we believe this demonstrates the high unmet need for a non-PSMA prostate cancer therapy such as ATNM-400.

 

Continued:

“In August 2025, we received a letter from Novartis Pharmaceuticals Corporation (the “Novartis Letter”) that is incorporated in this Form 10-Q as an exhibit. In that letter, Novartis strongly objected to statements that Actinium made comparing ATNM-400 and Pluvicto®. Given that ATNM-400 is in preclinical development and that we clearly indicated as such, we believe that the Novartis Letter is highly unusual. We believe the particular statements cited by Novartis were not misleading and were accurate depictions of our research findings that evaluated ATNM-400 versus 177Lu-PSMA-617, the active agent in Pluvicto® as well as 225Ac-PSMA-617, a targeted radiotherapy that is not yet approved but is being evaluated by multiple companies including Novartis. As we have reported, ATNM-400 demonstrated superior tumor control and improved overall survival in preclinical studies in prostate cancer bearing animals compared to 177Lu-PSMA-617. In addition, ATNM-400 demonstrated efficacy in prostate cancer tumors that developed resistance to 177Lu-PSMA-617. Therefore, we do not agree with any of the claims made in the Novartis Letter and do not believe Novartis has requisite legal authority or basis to challenge Actinium. Therefore, we have not responded to Novartis but reserve all rights. We believe patients with mCRPC have high unmet needs that are not addressed by current therapies including Pluvicto® and intend to continue to develop ATNM-400 with the goal of addressing these patient needs.

 

Continued:

“With the only approved targeted radiotherapy in prostate cancer moving up in the treatment paradigm with very few differentiated products in clinical development, we believe there is a significant potential market opportunity for ATNM-400. Currently, over 30 PSMA-targeted radiotherapies are in various stages of development, of which few offer a substantial efficacy advantage compared to Pluvicto®. Re-treatment with PSMA-targeting agents has not yet been supported substantially in controlled clinical trials and could be less effective than targeting a different antigen due to potential reduction of PSMA surface expression as well as increased tumor heterogeneity following initial PSMA-targeted therapy.

 

Continued:

“We have demonstrated that ATNM-400’s differentiated target is expressed and druggable following ARPI therapy and PSMA radiotherapy. We believe ATNM-400 can therefore target a significant subset of the mCRPC patient population with aggressive disease who progressed on second generation ARPIs or have had no response to or progressed on Lu-177 labelled PSMA-targeted therapy. As ATNM-400 does not target PSMA, xerostomia or dry mouth, which can be a significant quality of life issue for patients with metastatic prostate cancer receiving PSMA-targeted radiotherapies as PSMA is expressed on salivary glands, would not be expected. Additionally, the antigen targeted by ATNM-400 is implicated in a pathway leading to ARPI-resistance in mCRPC patients and expression increases post-ARPI treatment; therefore, along with the tumor suppressing ability of Ac-225, ATNM-400 displays a compelling mechanism for synergy with ARPIs. This mechanistic synergy is supported by the complete tumor regression in 40 percent of tumor bearing animals treated with the combination of ATNM-400 and the ARPI enzalutamide. As a result, we believe ATNM-400 has the potential to address critical gaps in prostate cancer treatment as a monotherapy or in combination or sequenced with other therapeutic modalities.”

 

SEC filing https://ir.actiniumpharma.com/all-sec-filings#document-3317-0001213900-25-110979

 

Looking at other companies in the market which are taking a different approach, in September, Lila Biologics an AI/ML-driven protein therapeutics biotech company announced a global licensing and multi-target research collaboration with Eli Lilly and Company ( NYSE: LLY) focused on the discovery, development, and commercialization of novel radioligand therapies (RLTs) for imaging and treatment of solid tumors. Lila also announced the launch of its two protein therapeutic platforms, driven by artificial intelligence (AI) and machine learning (ML), to combat cancer and non-oncology diseases. Lila’s targeted radiotherapy (TRT)/oncology platform for solid tumors and long-acting injectables (LAI) platform for non-oncology conditions are utilizing Lila’s proprietary AI/ML-powered protein design engine to create the foundation for new drug discovery and breakthrough treatments for patients.

 

From the news:

“We are on a mission to transform patient care by harnessing machine learning-powered protein design and advanced technologies to deliver life-changing therapies to patients,” said Jake Kraft, CEO and co-founder of Lila Biologics. “Lila’s core technology goes beyond ML-enabled design of high-affinity binders, and we’ve fine-tuned our engine to deliver precision targeted proteins with optimized drug-like properties that have the potential to unlock a new generation of treatments that dramatically improve patients’ quality of life and extend survival time.”

 

Earlier in the year, Eli Lilly and Company ( NYSE: LLY) entered into another collaboration in the sector.  AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly and Company to research and develop innovative treatments for various cancers.

 

From the news:

Under this new agreement, the parties will leverage AdvanCell’s proprietary Pb-212 production technology and radionuclide development infrastructure and Lilly’s drug candidate programs and extensive expertise in drug development to facilitate the development and accelerate the clinical advancement of an expanded portfolio of targeted alpha therapies.

 

Continued:

AdvanCell’s competitive advantage in technology development and the infrastructure it has built to accelerate early-stage clinical trials in Australia enables AdvanCell to rapidly develop and progress novel Pb-212-containing radiotherapeutics from discovery into clinical trials.

 

Continued:

“This collaboration with Lilly represents a significant milestone for AdvanCell, recognizing our company as one of the leaders in the Pb-212 targeted alpha therapy space,” said Andrew Adamovich, CEO of AdvanCell. “By combining our groundbreaking isotope production capabilities, our team’s expertise and infrastructure with Lilly’s pharmaceutical and oncology expertise and global scale, we aim to bring transformative treatments to patients with hard-to-treat cancers. It is especially pleasing to continue and expand our existing relationship.”

Research biotech and medical device/ tech stocks news and info at Investorideas.com

https://www.investorideas.com/BIS/

 

Disclaimer/Disclosure: This article featuring Actinium Pharmaceuticals, Inc. (ATNM) is paid for content. Our site does not make recommendations for purchases or sale of stocks, services or products. This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas https://www.investorideas.com/Advertise/

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all.

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800-665-0411

 

 

 

AI Defense Stock VisionWave Holdings (Nasdaq: $VWAV) Expands IP Portfolio and Files Patent for WaveStrike; @VWAVInc

 

AI Defense Stock VisionWave Holdings (Nasdaq: $VWAV) Expands IP Portfolio and Files Patent for WaveStrike; @VWAVInc

 

WaveStrike  RF Computer-Vision Fire-Control Built for Real-World Combat Environments

 

Extends Vision-RF sensing technology into soldier- and vehicle-level fire-control that performs day or night, in all weather, and through obscurants — without exposing the operator

 

 

 

West Hollywood, CA – November 17, 2025—(Investorideas.com Newswire) Breaking Defense stock news- VisionWave Holdings, Inc. (Nasdaq: VWAV) today announced the filing of U.S. Provisional Patent Application No. 63/892,721, titled “AI-Assisted Multi-Modal RF Fire-Control System for All-Domain Target Engagement.”

 

The new application expands VisionWave’s Vision-RF patent portfolio with a rifle-mountable RF-sensing module that converts radio-frequency (RF) returns into real-time, visualized situational awareness and predictive fire-control cues.

 

Operating day and night and in all weather or obscured conditions where electro-optical “smart” sights may experience degraded performance, the system’s RF-based, AI-driven computer-vision engine transforms complex RF scene data into a simple red/green “fire-eligible” cue and predictive-lead solution for soldier weapons, vehicle turrets, remote-weapon stations (RWS), and potential future air- and sea-platform integrations.

 

Paid News Dissemination on behalf of VWAV 

 

Read this news, featuring VWAV in full at https://www.investorideas.com/CO/BNIX/news/2025/11171-ai-defense-stock-vwav-wavestrike-rf-fire-control-patent.asp

 

Why RF-Native Fire-Control Matters

WaveStrike, built on VisionWave’s multi-patented Vision-RF core technology, transforms RF waveforms into image-like data without the use of cameras.

 

This RF-first approach provides inherent range and Doppler information, enabling intended detection, classification, tracking, and firing-solution computation against moving or static threats — even in various environmental conditions, including reduced visibility.

 

By contrast, optics-based systems rely on infrared illumination at night and laser rangefinders to calculate distance — techniques that may increase the risk of exposing a soldier’s position and experience performance degradation in obscurants, making them less effective for certain combat conditions.

 

VisionWave’s RF-native design requires no active IR or laser emissions, minimizing tactical signature while aiming to support sustained target tracking and fire-control decision-making. Because the system measures range as part of the RF solution itself, it is designed to provide range-informed targeting under certain conditions.

 

“With extensive combat experience, it’s clear that systems must be built to perform in real combat environments — day and night — allowing operators to see the unseen from a safe distance,” said Noam Kenig, Chief Executive Officer of VisionWave. “WaveStrike brings RF-native computer vision to the sensor-to-shooter loop, with the goal of reducing engagement timelines and supporting improved first-shot probability regardless of weather or visibility — all without exposing the operator.

 

By eliminating dependence on active optics and providing a clear, operator-centric cue, we’re delivering a potentially advantageous capability that is intended to operate in conditions where optical systems may be limited — across soldier weapons, vehicle turrets, RWS platforms, and ultimately air and maritime systems.”

 

How WaveStrike and Vision-RF Work (Technical Highlights)

• RF Computer Vision: RF waveforms are reconstructed into a dense 3-D scene fused by VisionWave’s Evolved Intelligence™ (EI) on-edge stack, intended to enable range-informed target localization.
• Edge Cognitive Fire-Control: Low-latency AI filters clutter, sustains lock in dense environments, and computes predictive aim points and lead solutions for agile aerial and ground threats.
• Human-in-the-Loop: Micro-correction arrows and a red-to-green confidence indicator ensure the operator remains firmly in control.
• ROE & Accountability: Customizable rules-of-engagement logic and tamper-evident logs provide auditability and command oversight.
• Modular Scalability: Architecture is designed to scale from compact rifle modules to crew-served weapons, vehicle integrations, naval arrays, and networked RWS clusters.

 

“Vision-RF reconstructs stabilized, visualized feeds in real time by converting RF returns through a temporal-spatial EI stack,” said Dr. Danny Rittman, Chief Technology Officer of VisionWave. “That native 3-D RF data provides range and motion cues that optical systems simply can’t replicate in degraded environments. WaveStrike uses this to deliver predictive fire-control recommendations — even in certain material-penetrating scenarios — while keeping operators safely out of harm’s way.”

 

Planned Development and Trials

VisionWave plans to advance development of Vision-RF following Q4 2025, began advanced system development of Vision-RF in Q4 2025, following completion of a functional prototype that demonstrated RF signal reconstruction into visualized outputs in controlled settings.

Field trials with select defense agencies are currently anticipated in 2026 or later, including demonstrations of soldier-scale rifle modules, vehicle integrations, and RWS implementations as part of an incremental qualification program.

 

Why This Matters to Operators and Programs

• Persistent Sensing: RF-native solutions are designed to support detection and tracking when optical systems experience reduced performance.
• Lower Tactical Signature: No IR illuminators or laser rangefinders —reduce active emissions.
• Broader Operating Envelope: Day/night, all-weather, and through-obscurant performance aims to support extended operational conditions.
• Networked Scalability: Modular design supports rapid integration across dismounted, vehicle, and fixed-site platforms.

 

About VisionWave Holdings, Inc.

VisionWave Holdings, Inc. (Nasdaq: VWAV) is a defense-technology company specializing in AI-powered sensing, on-edge autonomy, and threat-response systems.

Its portfolio includes super-resolution radar, multispectral/RF imaging, and the Evolved Intelligence™ (EI) engine for real-time perception, prediction, and control across air, land, and sea.

 

Important Notes on Patent Status

A provisional patent application establishes a priority date but is not examined and does not grant patent rights.

 

Any ultimate scope of protection, performance claims, or deployment timing is uncertain and subject to change. VisionWave may file corresponding non-provisional applications within the statutory period to pursue full patent protection.

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including without limitation statements regarding the anticipated capabilities of Vision-RF and WaveStrike, development timelines, planned integrations, and patent protection.  Words such as “will,” “expects,” “believes,” “potential,” “anticipated,” and similar expressions identify forward-looking statements. Actual outcomes may differ materially. Forward-looking statements are based on current expectations and are subject to risks and uncertainties described in VisionWave’s filings with the U.S. Securities and Exchange Commission. VisionWave undertakes no obligation to update these statements except as required by law. See VisionWave’s most recent Form 10-K and 10-Q for a fuller list of risk factors. The Company undertakes no obligation to update these statements.

 

Investor Contact: investors@vwav.inc

Website: https://www.vwav.inc

 

VisionWave is a Featured Defense stock on Investorideas.com

Research more defense stocks at Investorideas stock directory  https://www.investorideas.com/Companies/HomelandDefense/stock_list.asp

 

Disclaimer/Disclosure: VisionWave Holdings, Inc. is  a paid for featured defense company on Investorideas.com. Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all.

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas https://www.investorideas.com/Advertise/

 

Follow & Contact

Follow us on X: @investorideas   @stocknewsbites

Facebook: https://www.facebook.com/Investorideas

YouTube: https://www.youtube.com/c/Investorideas